Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P00846
UPID:
ATP6_HUMAN
Alternative names:
F-ATPase protein 6
Alternative UPACC:
P00846; Q34772; Q5S8W5; Q5S9E7; Q5S9I6; Q5SA31; Q6RPB7; Q6VHC0; Q6VHE0; Q6WQF4; Q7YCC1; Q7YCF8; Q7YCG1; Q85KU8; Q85KX1; Q85L05; Q8HNQ4; Q8HNQ8; Q8WCX6; Q9B2U5; Q9B2Z2
Background:
ATP synthase subunit a, also known as F-ATPase protein 6, plays a pivotal role in cellular energy production. It is a key component of the mitochondrial membrane ATP synthase (Complex V), which generates ATP from ADP, utilizing a proton gradient created by the respiratory chain.
Therapeutic significance:
Mutations in ATP synthase subunit a are linked to a spectrum of mitochondrial disorders, including Neuropathy, Ataxia, and Retinitis Pigmentosa, and Leigh syndrome. These associations underscore the protein's potential as a target for therapeutic interventions in mitochondrial diseases.